Kyowa Kirin drops rolofylline as istradefylline progresses
This article was originally published in Scrip
Executive Summary
Kyowa Hakko Kirin has discontinued the Japanese development of rolofylline (KW-3902) following the failure of the molecule earlier this year in a Phase III trial conducted by licensee Merck & Co.